X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA MERCK LTD ALEMBIC PHARMA/
MERCK LTD
 
P/E (TTM) x 26.6 26.1 101.9% View Chart
P/BV x 6.1 2.9 207.7% View Chart
Dividend Yield % 0.8 1.0 80.2%  

Financials

 ALEMBIC PHARMA   MERCK LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
MERCK LTD
Dec-16
ALEMBIC PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs7921,060 74.7%   
Low Rs443623 71.1%   
Sales per share (Unadj.) Rs167.0632.4 26.4%  
Earnings per share (Unadj.) Rs38.245.7 83.5%  
Cash flow per share (Unadj.) Rs42.062.3 67.4%  
Dividends per share (Unadj.) Rs4.0011.00 36.4%  
Dividend yield (eoy) %0.61.3 49.6%  
Book value per share (Unadj.) Rs84.9388.8 21.8%  
Shares outstanding (eoy) m188.5216.60 1,135.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.71.3 277.8%   
Avg P/E ratio x16.218.4 87.9%  
P/CF ratio (eoy) x14.713.5 108.9%  
Price / Book Value ratio x7.32.2 336.0%  
Dividend payout %10.524.1 43.6%   
Avg Mkt Cap Rs m116,38313,969 833.2%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m4,2141,487 283.4%   
Avg. sales/employee Rs ThNM6,631.9-  
Avg. wages/employee Rs ThNM939.2-  
Avg. net profit/employee Rs ThNM479.4-  
INCOME DATA
Net Sales Rs m31,48710,498 299.9%  
Other income Rs m55242 22.7%   
Total revenues Rs m31,54210,741 293.7%   
Gross profit Rs m10,0601,135 886.1%  
Depreciation Rs m722276 262.1%   
Interest Rs m370-   
Profit before tax Rs m9,3561,102 848.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,160343 629.2%   
Profit after tax Rs m7,194759 948.0%  
Gross profit margin %31.910.8 295.4%  
Effective tax rate %23.131.1 74.1%   
Net profit margin %22.87.2 316.1%  
BALANCE SHEET DATA
Current assets Rs m15,0666,410 235.1%   
Current liabilities Rs m7,6748,828 86.9%   
Net working cap to sales %23.5-23.0 -101.9%  
Current ratio x2.00.7 270.4%  
Inventory Days Days6758 116.1%  
Debtors Days Days4138 105.8%  
Net fixed assets Rs m8,2371,406 585.7%   
Share capital Rs m377166 227.1%   
"Free" reserves Rs m15,4166,286 245.2%   
Net worth Rs m16,0056,455 248.0%   
Long term debt Rs m00-   
Total assets Rs m24,5948,828 278.6%  
Interest coverage x255.2NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.31.2 107.7%   
Return on assets %29.48.6 342.0%  
Return on equity %44.911.8 382.3%  
Return on capital %58.717.1 343.6%  
Exports to sales %55.78.3 673.1%   
Imports to sales %10.421.0 49.5%   
Exports (fob) Rs m17,551869 2,018.7%   
Imports (cif) Rs m3,2832,209 148.6%   
Fx inflow Rs m17,811959 1,857.6%   
Fx outflow Rs m5,3182,612 203.6%   
Net fx Rs m12,493-1,653 -755.7%   
CASH FLOW
From Operations Rs m9,3041,070 869.2%  
From Investments Rs m-3,105-750 414.1%  
From Financial Activity Rs m-1,959-150 1,307.8%  
Net Cashflow Rs m4,240171 2,481.0%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 2.9 18.2 15.9%  
FIIs % 9.1 1.0 910.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 29.1 47.8%  
Shareholders   49,328 28,591 172.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - CLARIS LIFESCIENCES COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS